Injection Pen Market Size was valued at USD 43.2 billion in 2021 and is projected to grow from USD 46.18 Billion in 2022 to USD 74.4 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.5% during the forecast period (2023 - 2032).The need for injectable pen technologies has increased to properly address the rising patient pool and promote treatment adherence are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market expansion is being fueled by the increasing demand for injectable pen technologies in order to effectively serve a larger patient population and boost treatment adherence. Injectable drugs are meant to be given to patients as quickly and painlessly as possible with the help of injection pens. The gadget is lightweight and compact enough to fit in the palm of your hand, and it may be used to administer medication for a wide range of medical ailments. The rising incidence of chronic disorders like diabetes and osteoporosis is expected to boost the injection pen market throughout the predicted time frame.
Another factor contributing to the expansion of the market is the rising popularity of injectable pens as an alternative to the more conventional vial and needle method. The incidence of chronic diseases has increased in recent decades. Diabetes, cardiovascular disease, osteoporosis, and multiple sclerosis all require injections, either daily or monthly. Chronic conditions that need regular dosing are well suited for injector pens.
Another aspect driving the market forward is the increasing use of innovative reusable injection pens among diabetic patients. In addition, the increasing popularity of automated injection pens is a key factor in the expansion of the injection pen market. Medical professionals are increasingly using automated injection pens due to their ease of use, precision, safety, and convenience in medication delivery. Injection pens are in high demand across the world, not just in the wealthy nations where the aging population is increasingly at risk for conditions like diabetes and cancer. The expansion of the market can be attributed to these elements.
In January 2024, Mounjaro, medication pre-filling in an injection pen, Lilly opened a new tab after being given the green light and announced it would take only weeks to get the dosage for British patients. Mounjaro is known to combat diabetes and obesity. A US pharmaceutical company indicated that Medicines & Healthcare Products Regulatory Agency (MHRA) approval made Britain the first major market where the drug could be used in a convenient multi-shot pen referred to as Kwikpen.
In April 2023, Mounjaro subcutaneous injectable 2.5 mg/ 5 mg ATEOS was launched in Japan by Mitsubishi Tanabe Pharma Corporation (MTPC) and Eli Lilly Japan. Once a week, the medicine is injected under your skin using a single-use autoinjector device (ATEOS). Pressing an injection button of a particular pen injector loads needle with medicine once, which inserts beneath patient’s skin automatically. There is no need for the patient to apply medication or handle a needle.
In February 2023, Phillips-Medisize increased its product line to include a disposable pen injector, which is a subsidiary of Molex company. The firm introduced this new addition of disposable pen injectors into its business products. Phillips-Medisize supplies pharma firms with an environmentally competitive pen injector suitable for highly productive manufacturing and accelerates them through the market at lower costs.
In February 2023 Sanofi’s SoloSmart can be attached to either SoloStar or DoubleStar insulin injection pens. It shows when drugs have been administered together with quantities injected per time period. This collaboration has enabled Glooko app users to visualize their data, making it easier for Sanofi to track this information on behalf of clients within their mobile devices while they are away from home.
AstraZeneca and Amgen’s Tezspire (tezepelumab) pre-filled pen was approved by U.S Food and Drug Administration (FDA) in the United States on a pre-filled basis in February 2023. Tezspire pre-filled pen is used for self-administration in patients aged 12 years and older with severe asthma. Therefore, launching the new injection pen device could be vital as it will create a strong presence for the company among others existing within this industry.
In October 2020, Ypsomed AG produced the world’s first zero-carbon emission prefilled autoinjector called YpsoMate Zero.
The injection pen market segmentation, based on type, disposable injection pens. The disposable injection pen segment held the majority share in 2021 in respect to the injection pen market revenue. This is explained by the disposable injection pens' high level of affordability and safety. Due to the reusability of the injections, the disposable injection pens enhance safety against blood-borne infections and can only be used once. The disposable injection pen market has been expanding over the past few years because to factors such ease of accessibility, rising consumer awareness, rising healthcare costs, and an increase in the prevalence of diseases associated to insulin.
The injection pen market segmentation, based on product, includes insulin pens and pen needles. The insulin pen segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the increasing diabetes patients. As per the International diabetes federation, the diabetic population is expected to reach at 643 million by 2030 ly.
For Instance: Reusable smart insulin pens, are now readily accessible and come with an intuitive smartphone app that can help diabetics better control their insulin dosage. Additionally, these are frequently more affordable, simpler to use, and offer a number of advantages and enhancements for patients who rely on insulin to treat their diabetes; as a result, demand for such innovative technologies is only increasing, which is fueling market revenue growth.
The injection pen market data has been bifurcated by therapy in diabetes. The diabetes segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The increasing prevalence of diabetes, rising awareness of insulin pens among diabetic patients, the growing availability of insulin pens, and the increasing elderly population are the major contributors in the market growth.
The World Health Organization claims that diabetes is a significant contributor to kidney failure, blindness, and stroke. Additionally, cardiovascular illnesses are the main cause of death worldwide, accounting for 32% of all fatalities. Therefore, it is anticipated that the market for injectable pens will experience growth due to the rising prevalence of different chronic and non-communicable diseases among the population.
Based on Distribution Channel, the injection pen industry has been segmented into hospital and pharmacies. Hospitals held the largest segment share in 2021, owing to the rapid adoption of injection pen. Moreover, increasing government initiatives to improve the healthcare infrastructure, and the growing number of diabetes patients is expected to boost the market during the assessed timeline. Improved consumer spending on healthcare, rising disposable income, increased consumer knowledge of the use of injection pens are the main drivers of this market's expansion.
July 2023:Injector pens for the low-cost insulins produced by Civica, Inc. will be manufactured and supplied by Ypsomed AG beginning in July 2023. Prior to this announcement, Civica stated that it planned to manufacture three insulin biosimilars: glargine, lispro, and aspart. Both vials and prefilled pens will be made available for purchase. The business hopes to sell the insulins at far lower prices than the competition. Civica will be able to help make self-administered treatment more affordable for Americans with diabetes with the assistance of Ypsomed, a recognized injectable device specialist with over 35 years of experience.
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Injection Pen market accounted for USD 18.79 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the growing diabetic patients and rising elderly population across the region.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: INJECTION PEN MARKET SHARE BY REGION 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe injection pen market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, an ageing population, and an increase in incidence of diabetic disease, cancer. Further, the Germany injection pen market held the largest market share, and the UK injection pen market was the fastest growing market in the European region
The Asia-Pacific injection pen Market is expected to grow at the fastest CAGR from 2022 to 2030. Increasing rates of chronic diseases due to the unhealthy food, physical inactivity, and the increasing consumption of tobacco and alcohol in youth. Moreover, China injection pen market held the largest market share, and the India injection pen market was the fastest growing market in the Asia-Pacific region.
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Injection Pen market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the injection pen industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the injection pen industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, injection pen industry has provided medicine with some of the most significant benefits. The injection pen market major player such as Novo Nordisk, Eli Lilly, Sanofi, Merck, Ypsomed, AstraZeneca, Hoffman-La Roche, Becton Dickinson and Company, Owen Mumford, Novartis and others are working to expand the market demand by investing in research and development activities.
Sanofi, is a cutting-edge healthcare organisation with a single goal: to use science's wonders to enhance people's lives. Company’s team works to change the way medication is delivered to patients by making the seemingly impossible feasible. It protect millions of people with potentially life-saving vaccines and treatments, and we give them inexpensive access to our medications in some of the world's poorest nations.
For Instance: April 2020, the FDA approved Sanofi (Francenovel )'s Dupixent prefilled pen for use in the management of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. The pen can be used at home for administration.
Also, In June of this year, Sanofi (France), the manufacturer of the Toujeo SoloStar Pens, received approval in Europe.
Merck is a major provider of solutions and services for the study, creation, and distribution of pharmaceutical and biotechnology drug therapies for the worldwide life science market. Together with its coworkers, clients, and stakeholders, company use science to improve life and health. Researchers must have access to cutting-edge equipment, services, and knowledge in order to conduct tests and design new products before they can create scientific breakthroughs.
With best-in-class solutions for pharmaceutical development and manufacture, a fully integrated service organisation to support CDMO and contract testing across conventional and cutting-edge modalities, and one of the broadest portfolios in the sector for scientists, we lead the market.
For Instance: January 2019, Merck KGaG released Pergoveris in as an injectable gonadotropin pen for reproductive therapy (Germany).
Key Companies in the injection pen market includes
Injection Pen Industry Developments
October 2017: Eli Lilly launched Humalog Junior KwikPen for the U.S. diabetic patients.
2019: Becton, Dickinson and company (BD) have introduced the BD Stevia, a thorough two-step disposable auto-injector. The parental drug association in 2019 universe of injection devices and pre-filled syringes conference saw the unveiling of this platform device, which is a combination of pre-fillable syringe and insulin auto-injector pen in one integrated system.
As per TEVA PHARMACEUTICALS USA,INC, the AJOVY auto-injector has been commercial launched in United States. This kind of injection pen is designed to treat migraines in adults as per preventative measure.
| Report Attribute/Metric | Details |
| Market Size 2021 | USD 43.2 billion |
| Market Size 2022 | USD 46.18 billion |
| Market Size 2032 | USD 74.4 billion |
| Compound Annual Growth Rate (CAGR) | 6.5 % (2023-2032) |
| Base Year | 2021 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 & 2020 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Product, Therapy, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novo Nordisk, Eli Lilly, Sanofi, Merck, Ypsomed, AstraZeneca, Hoffman-La Roche, Becton Dickinson and Company, Owen Mumford, Novartis |
| Key Market Opportunities | Increasing need for injectable pen technologies Rising diabetic patients Increasing disposable income |
| Key Market Dynamics | Increasing awareness regarding injectable pens Government initiatives towards health sector |
Frequently Asked Questions (FAQ) :
The injection pen market size was valued at USD 43.2 billion in 2021.
The market is projected to grow at a CAGR of 6.5% during the forecast period, 2023-2032.
North America had the largest share in the market.
The key players in the market are Novo Nordisk, Eli Lilly, Sanofi, Merck, Ypsomed, AstraZeneca, Hoffman-La Roche, Becton Dickinson and Company, Owen Mumford, Novartis.
The disposable injection pen category dominated the market in 2021.
The diabetes had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
